OPKO Health Announces Executive Appointments
April 01 2014 - 8:25AM
Business Wire
- Adam Logal Appointed Senior Vice
President, Chief Financial Officer
- Arie Gutman Appointed Chief
Executive Officer of OPKO’s Active Pharmaceutical Ingredient and
Chemical Development Division
OPKO Health, Inc. (NYSE:OPK) today announced the appointment of
Adam Logal as Senior Vice President, Chief Financial Officer.
Additionally, Arie Gutman Ph.D. was appointed Chief Executive
Officer of OPKO’s newly created Active Pharmaceutical Ingredient
and Chemical Development Division.
Mr. Logal, currently Vice President, Finance, Chief Accounting
Officer and Treasurer, succeeds Juan F. Rodriguez, who will
continue to provide services to OPKO as a consultant while he
pursues personal business interests. “Adam has been a key leader in
our organization since our inception in 2007. His knowledge of our
business, versatility as a finance leader and his strategic
insights are valued by leaders across the Company,” said Phillip
Frost, M.D., Chairman and Chief Executive Officer of OPKO. “I am
delighted that Adam will continue to help lead the Company through
our near term commercial opportunities and help position us for
long-term success.”
Dr. Gutman founded FineTech Pharmaceutical Ltd. (“FineTech”), a
highly profitable FDA approved business specializing in the
development and manufacture of complex active pharmaceutical
ingredients which OPKO acquired in December 2011. Under Dr.
Gutman’s leadership as its President and CEO, FineTech has
partnered with generic pharmaceutical companies initiating several
“first to file” paragraph IV opportunities that led to successful
launches of specialty generic drugs. With his appointment as Chief
Executive Officer of OPKO’s Active Pharmaceutical Ingredient and
Chemical Development Division, Dr. Gutman will lead efforts to
develop additional chemistry based businesses and also ensure
in-house availability of advanced synthetic capabilities for OPKO’s
internal drug and diagnostic development programs.
About OPKO
OPKO is a multinational biopharmaceutical and diagnostics
company that seeks to establish industry leading positions in
large, rapidly growing markets by leveraging its discovery,
development and commercialization expertise and novel and
proprietary technologies.
This press release contains "forward-looking statements," as
that term is defined under the Private Securities Litigation Reform
Act of 1995 (PSLRA), which statements may be identified by words
such as "expects," "plans," "projects," "will," "may,"
"anticipates," "believes," "should," "intends," "estimates," and
other words of similar meaning, including all non-historical
statements about our expectations, beliefs or intentions regarding
our business, technologies and products, financial condition,
strategies, prospects, growth opportunities, and management. Many
factors could cause our actual activities or results to differ
materially from the activities and results anticipated in
forward-looking statements. These factors include those described
in our filings with the Securities and Exchange Commission, and
risks inherent in funding, developing and obtaining regulatory
approvals of new, commercially-viable and competitive products and
treatments. In addition, forward-looking statements may also be
adversely affected by general market factors, competitive product
development, product availability, federal and state regulations
and legislation, the regulatory process for new products and
indications, manufacturing issues that may arise, patent positions
and litigation, among other factors. The forward-looking statements
contained in this press release speak only as of the date the
statements were made, and, except as required by applicable law, we
do not undertake any obligation to update forward-looking
statements. We intend that all forward-looking statements be
subject to the safe-harbor provisions of the PSLRA.
OPKO Health, Inc.Steven D. Rubin or Adam Logal,
305-575-4100
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From Apr 2024 to May 2024
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From May 2023 to May 2024